(Q42851077)

English

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

scientific article published on 19 October 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Delphine Réa

2

0 references

François Guilhot

object named as

François Guilhot

4

0 references

author name string

François-Xavier Mahon

1

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Joëlle Guilhot

3

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Françoise Huguet

5

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Franck Nicolini

6

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Laurence Legros

7

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Aude Charbonnier

8

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Agnès Guerci

9

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Bruno Varet

10

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Gabriel Etienne

11

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Josy Reiffers

12

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Philippe Rousselot

13

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Intergroupe Français des Leucémies Myéloïdes Chroniques

14

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

publication date

19 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

1029-1035

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970233-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970233-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970233-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970233-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970233-3

7 January 2021

based on heuristic

inferred from DOI database lookup

BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using str

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970233-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970233-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970233-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970233-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Discontinuation of imatinib therapy after achieving a molecular response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970233-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970233-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970233-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Dynamics of chronic myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970233-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970233-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970233-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970233-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970233-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic myeloid leukemia stem cells: now on the run

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970233-3

7 January 2021

based on heuristic

inferred from DOI database lookup

In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970233-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970233-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(10)70233-3

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42851077&oldid=1972535931"